Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir

T. N. Kakuda, L. M. Page, P. L. Anderson, K. Henry, T. W. Schacker, F. S. Rhame, E. P. Acosta, R. C. Brundage, C. V. Fletcher

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Conventional antiretroviral therapy involves administration of standard fixed doses to adults and adolescents. This approach ignores interindividual variability in pharmacokinetics and results in substantial differences in systemic concentrations among patients. Thus, variability in systemic concentrations contributes to variability in response to therapy. This study was designed to evaluate the feasibility and safety of a regimen of zidovudine, lamivudine, and indinavir designed to achieve select target concentrations versus standard dose therapy. Twenty-four antiretroviral-naïve subjects completed the 24-week study; 13 received standard therapy, and 11 received concentration-controlled therapy. There were no differences in baseline characteristics. Oral clearance for all three drugs was not different between weeks 2 and 28; average ratios of week 2 oral clearance to week 28 oral clearance were 0.95, 1.09, and 1.06 for zidovudine, lamivudine, and indinavir, respectively, with 95% confidence intervals including 1. The selected target concentrations were average steady-state concentrations of 0.19 mg/liter for zidovudine and 0.44 mg/liter for lamivudine and a trough concentration of 0.15 mg/liter for indinavir; mean concentrations achieved at week 28 in the concentration-controlled arm were 0.20, 0.54, and 0.19 mg/liter, respectively. Concentration-controlled therapy significantly reduced interpatient variability in zidovudine concentrations and significantly increased indinavir concentrations. There was no difference in adverse drug effects or adherence. This investigation has provided a pharmacologic basis for concentration-controlled therapy by demonstrating that it is feasible and has a safety profile no different from that of standard therapy. Additional studies to evaluate the virologic effect of the concentration-controlled approach to antiretroviral therapy are warranted.

Original languageEnglish (US)
Pages (from-to)236-242
Number of pages7
JournalAntimicrobial Agents and Chemotherapy
Volume45
Issue number1
DOIs
StatePublished - Jan 16 2001

Fingerprint

Indinavir
Lamivudine
Zidovudine
Pharmacology
Therapeutics
Safety
Pharmaceutical Preparations
Pharmacokinetics
Confidence Intervals

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir. / Kakuda, T. N.; Page, L. M.; Anderson, P. L.; Henry, K.; Schacker, T. W.; Rhame, F. S.; Acosta, E. P.; Brundage, R. C.; Fletcher, C. V.

In: Antimicrobial Agents and Chemotherapy, Vol. 45, No. 1, 16.01.2001, p. 236-242.

Research output: Contribution to journalArticle

Kakuda, TN, Page, LM, Anderson, PL, Henry, K, Schacker, TW, Rhame, FS, Acosta, EP, Brundage, RC & Fletcher, CV 2001, 'Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir', Antimicrobial Agents and Chemotherapy, vol. 45, no. 1, pp. 236-242. https://doi.org/10.1128/AAC.45.1.236-242.2001
Kakuda, T. N. ; Page, L. M. ; Anderson, P. L. ; Henry, K. ; Schacker, T. W. ; Rhame, F. S. ; Acosta, E. P. ; Brundage, R. C. ; Fletcher, C. V. / Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir. In: Antimicrobial Agents and Chemotherapy. 2001 ; Vol. 45, No. 1. pp. 236-242.
@article{801cc3463bc24dff8b9f06c3eda26ed1,
title = "Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir",
abstract = "Conventional antiretroviral therapy involves administration of standard fixed doses to adults and adolescents. This approach ignores interindividual variability in pharmacokinetics and results in substantial differences in systemic concentrations among patients. Thus, variability in systemic concentrations contributes to variability in response to therapy. This study was designed to evaluate the feasibility and safety of a regimen of zidovudine, lamivudine, and indinavir designed to achieve select target concentrations versus standard dose therapy. Twenty-four antiretroviral-na{\"i}ve subjects completed the 24-week study; 13 received standard therapy, and 11 received concentration-controlled therapy. There were no differences in baseline characteristics. Oral clearance for all three drugs was not different between weeks 2 and 28; average ratios of week 2 oral clearance to week 28 oral clearance were 0.95, 1.09, and 1.06 for zidovudine, lamivudine, and indinavir, respectively, with 95{\%} confidence intervals including 1. The selected target concentrations were average steady-state concentrations of 0.19 mg/liter for zidovudine and 0.44 mg/liter for lamivudine and a trough concentration of 0.15 mg/liter for indinavir; mean concentrations achieved at week 28 in the concentration-controlled arm were 0.20, 0.54, and 0.19 mg/liter, respectively. Concentration-controlled therapy significantly reduced interpatient variability in zidovudine concentrations and significantly increased indinavir concentrations. There was no difference in adverse drug effects or adherence. This investigation has provided a pharmacologic basis for concentration-controlled therapy by demonstrating that it is feasible and has a safety profile no different from that of standard therapy. Additional studies to evaluate the virologic effect of the concentration-controlled approach to antiretroviral therapy are warranted.",
author = "Kakuda, {T. N.} and Page, {L. M.} and Anderson, {P. L.} and K. Henry and Schacker, {T. W.} and Rhame, {F. S.} and Acosta, {E. P.} and Brundage, {R. C.} and Fletcher, {C. V.}",
year = "2001",
month = "1",
day = "16",
doi = "10.1128/AAC.45.1.236-242.2001",
language = "English (US)",
volume = "45",
pages = "236--242",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "1",

}

TY - JOUR

T1 - Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir

AU - Kakuda, T. N.

AU - Page, L. M.

AU - Anderson, P. L.

AU - Henry, K.

AU - Schacker, T. W.

AU - Rhame, F. S.

AU - Acosta, E. P.

AU - Brundage, R. C.

AU - Fletcher, C. V.

PY - 2001/1/16

Y1 - 2001/1/16

N2 - Conventional antiretroviral therapy involves administration of standard fixed doses to adults and adolescents. This approach ignores interindividual variability in pharmacokinetics and results in substantial differences in systemic concentrations among patients. Thus, variability in systemic concentrations contributes to variability in response to therapy. This study was designed to evaluate the feasibility and safety of a regimen of zidovudine, lamivudine, and indinavir designed to achieve select target concentrations versus standard dose therapy. Twenty-four antiretroviral-naïve subjects completed the 24-week study; 13 received standard therapy, and 11 received concentration-controlled therapy. There were no differences in baseline characteristics. Oral clearance for all three drugs was not different between weeks 2 and 28; average ratios of week 2 oral clearance to week 28 oral clearance were 0.95, 1.09, and 1.06 for zidovudine, lamivudine, and indinavir, respectively, with 95% confidence intervals including 1. The selected target concentrations were average steady-state concentrations of 0.19 mg/liter for zidovudine and 0.44 mg/liter for lamivudine and a trough concentration of 0.15 mg/liter for indinavir; mean concentrations achieved at week 28 in the concentration-controlled arm were 0.20, 0.54, and 0.19 mg/liter, respectively. Concentration-controlled therapy significantly reduced interpatient variability in zidovudine concentrations and significantly increased indinavir concentrations. There was no difference in adverse drug effects or adherence. This investigation has provided a pharmacologic basis for concentration-controlled therapy by demonstrating that it is feasible and has a safety profile no different from that of standard therapy. Additional studies to evaluate the virologic effect of the concentration-controlled approach to antiretroviral therapy are warranted.

AB - Conventional antiretroviral therapy involves administration of standard fixed doses to adults and adolescents. This approach ignores interindividual variability in pharmacokinetics and results in substantial differences in systemic concentrations among patients. Thus, variability in systemic concentrations contributes to variability in response to therapy. This study was designed to evaluate the feasibility and safety of a regimen of zidovudine, lamivudine, and indinavir designed to achieve select target concentrations versus standard dose therapy. Twenty-four antiretroviral-naïve subjects completed the 24-week study; 13 received standard therapy, and 11 received concentration-controlled therapy. There were no differences in baseline characteristics. Oral clearance for all three drugs was not different between weeks 2 and 28; average ratios of week 2 oral clearance to week 28 oral clearance were 0.95, 1.09, and 1.06 for zidovudine, lamivudine, and indinavir, respectively, with 95% confidence intervals including 1. The selected target concentrations were average steady-state concentrations of 0.19 mg/liter for zidovudine and 0.44 mg/liter for lamivudine and a trough concentration of 0.15 mg/liter for indinavir; mean concentrations achieved at week 28 in the concentration-controlled arm were 0.20, 0.54, and 0.19 mg/liter, respectively. Concentration-controlled therapy significantly reduced interpatient variability in zidovudine concentrations and significantly increased indinavir concentrations. There was no difference in adverse drug effects or adherence. This investigation has provided a pharmacologic basis for concentration-controlled therapy by demonstrating that it is feasible and has a safety profile no different from that of standard therapy. Additional studies to evaluate the virologic effect of the concentration-controlled approach to antiretroviral therapy are warranted.

UR - http://www.scopus.com/inward/record.url?scp=0035173814&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035173814&partnerID=8YFLogxK

U2 - 10.1128/AAC.45.1.236-242.2001

DO - 10.1128/AAC.45.1.236-242.2001

M3 - Article

C2 - 11120972

AN - SCOPUS:0035173814

VL - 45

SP - 236

EP - 242

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 1

ER -